Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema
3
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. Methods: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. Results: In patients with the bevacizumab injection only, VA improved from 0.29 ± 0.18 to 0.48 ± 0.26 at 1 month and returned to 0.32 ± 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 ± 0.22to 0.52 ± 0.26 at 1 month and returned to 0.36 ± 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow‐up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. Conclusions: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
Abstract
Purpose: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. Methods: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. Results: In patients with the bevacizumab injection only, VA improved from 0.29 ± 0.18 to 0.48 ± 0.26 at 1 month and returned to 0.32 ± 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 ± 0.22to 0.52 ± 0.26 at 1 month and returned to 0.36 ± 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow‐up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. Conclusions: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
참고문헌 (28)
- Klein R, "The Wisconsin epidemiologic study of diabetic retinopathy.IV.Diabetic macular edema", Ophthalmology, 91, pp.1464~1474 (1984)
- "Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 98(5 Suppl), pp.766~785 (1991)
- Akduman L, "Laser photocoagulation of diabetic macular edema", Ophthalmic Surg Lasers, 28, pp.387~408 (1997)
- "Photocoagulation for diabetic macular edema.Early Treatment Diabetic Retinopathy Study report number 1.Early Treatment Diabetic Retinopathy Study Research Group", Arch Ophthalmol, 103, pp.1796~1806 (1985)
- "Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema.Early Treatment Diabetic Retinopathy Study Report Number 2.Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 94, pp.761~774 (1987)
- Wilson DJ, "Macular grid photocoagulation.An experimental study on the primate retina", Arch Ophthalmol, 106, pp.100~105 (1988)
- Arnarsson A, "Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion", Invest Ophthalmol Vis Sci, 41, pp.877~879 (2000)
- Schatz H, "Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema", Arch Ophthalmol, 109, pp.1549~1551 (1991)
- Roider J, "Laser treatment of retinal diseases by subthreshold laser effects", Semin Ophthalmol, 14, pp.19~26 (1999)
- Jonas JB, "Intravitreal injection of triamcinolone for diffuse diabetic macular edema", Arch Ophthalmol, 121, pp.57~61 (2003)
- Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema", Ophthalmology, 109, pp.920~927 (2002)
- Haritoglou C, "Intravitreal bevacizumab(Avastin)therapy for persistent diffuse diabetic macular edema", Retina, 26, pp.999~1005 (2006)
- Arevalo JF, "Primary intravitreal bevacizumab(Avastin)for diabetic macular edema:results from the Pan-American Collaborative Retina Study Group at 6-month follow-up", Ophthalmology, 114, pp.743~750 (2007)
- Bonini-Filho MA, "Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema:a randomized clinical trial", Invest Ophthalmol Vis Sci, 46, pp.3845~3849 (2005)
- Jonas JB, "Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema", Ophthalmology, 113, pp.800~804 (2006)
- Cunningham ET Jr, "A phase II randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema", Ophthalmology, 112, pp.1747~1757 (2005)
- Lam DS, "Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema:six-month outcomes", Ophthalmology, 114, pp.2162~2167 (2007)
- 김영균, "당뇨황반부종의 종류에 따른 트리암시놀론 안내주입술의 임상분석", 대한안과학회지, 46(1), pp.13~13 (2005), 대한안과학회
- Otani T, "Patterns of diabetic macular edema with optical coherence tomography", Am J Ophthalmol, 127, pp.688~693 (1999)
- Avitabile T, "Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema", Am J Ophthalmol, 140, pp.695~702 (2005)
- Ahmadieh H, "Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled,randomized clinical trial", Graefes Arch Clin Exp Ophthalmol, 246, pp.483~489 (2008)
- 백종헌, "유리체황반견인을 동반한 당뇨황반부종에 대한 삼중치료의 단기 효과", 대한안과학회지, 49(12), pp.1941~1947 (2008), 대한안과학회
- Ferris FL 3rd, "Macular edema. A complication of diabetic retinopathy", Surv Ophthalmol, 28(Suppl), pp.452~461 (1984)
- Antcliff RJ, "The pathogenesis of edema in diabetic maculopathy", Semin Ophthalmol, 14, pp.223~232 (1999)
- Cunha-Vaz J, "Diabetic macular edema", Eur J Ophthalmol, 8, pp.127~130 (1998)
- Lobo C, "Novel imaging techniques for diabetic macular edema", Doc Ophthalmol, 97, pp.341~347 (1999)
- Yanoff M, "Pathology of human cystoid macular edema", Surv Ophthalmol, 28(Suppl), pp.505~511 (1984)
- Fine BS, "Macular edema and cystoid macular edema", Am J Ophthalmol, 92, pp.466~481 (1981)